Market Closed -
Other stock markets
|
After market 02:28:25 pm | |||
3.04 EUR | -1.30% | 3.02 | -0.66% |
Apr. 23 | Transcript : Heidelberg Pharma AG - Special Call | |
Mar. 27 | Heidelberg Pharma Wins US FDA Orphan Drug Designation for Multiple Myeloma Treatment | MT |
Sales 2024 * | 11.5M 12.29M | Sales 2025 * | 15M 16.04M | Capitalization | 144M 153M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | 12.5 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 9.57 x |
P/E ratio 2024 * |
-10.3
x | P/E ratio 2025 * |
-23.7
x | Employees | 95 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 16.94% |
Latest transcript on Heidelberg Pharma AG
1 day | -1.95% | ||
1 week | +2.70% | ||
Current month | -2.56% | ||
1 month | -1.94% | ||
3 months | -8.43% | ||
6 months | +6.67% | ||
Current year | -18.72% |
Managers | Title | Age | Since |
---|---|---|---|
Andreas Pahl
CEO | Chief Executive Officer | - | 11-12-31 |
Walter Miller
DFI | Director of Finance/CFO | - | 23-04-30 |
András Strassz
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-28 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 60 | 05-04-28 | |
Georg F. Baur
BRD | Director/Board Member | 74 | 00-12-13 |
Birgit Kudlek
BRD | Director/Board Member | 57 | 12-05-24 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 3.04 | -1.30% | 4 000 |
24-04-23 | 3.08 | +2.67% | 2,687 |
24-04-22 | 3 | 0.00% | 1,279 |
24-04-19 | 3 | +1.35% | 780 |
24-04-18 | 2.96 | 0.00% | 4,406 |
Delayed Quote Xetra, April 24, 2024 at 11:36 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-18.72% | 154M | |
-1.54% | 105B | |
+3.64% | 97.5B | |
+1.86% | 22.19B | |
-16.64% | 21.33B | |
-8.49% | 18.68B | |
-42.33% | 16.6B | |
-20.40% | 14.52B | |
+5.46% | 14.09B | |
+28.07% | 10.99B |
- Stock Market
- Equities
- HPHA Stock